SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001410578-23-001056
Filing Date
2023-05-12
Accepted
2023-05-12 08:32:24
Documents
68
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q fwbi-20230331x10q.htm   iXBRL 10-Q 1147705
2 EX-31.1 fwbi-20230331xex31d1.htm EX-31.1 12874
3 EX-31.2 fwbi-20230331xex31d2.htm EX-31.2 12875
4 EX-32.1 fwbi-20230331xex32d1.htm EX-32.1 8219
  Complete submission text file 0001410578-23-001056.txt   5954032

Data Files

Seq Description Document Type Size
5 EX-101.SCH fwbi-20230331.xsd EX-101.SCH 56930
6 EX-101.CAL fwbi-20230331_cal.xml EX-101.CAL 38909
7 EX-101.DEF fwbi-20230331_def.xml EX-101.DEF 223397
8 EX-101.LAB fwbi-20230331_lab.xml EX-101.LAB 485467
9 EX-101.PRE fwbi-20230331_pre.xml EX-101.PRE 354084
62 EXTRACTED XBRL INSTANCE DOCUMENT fwbi-20230331x10q_htm.xml XML 914445
Mailing Address 777 YAMATO ROAD SUITE 502 BOCA RATON FL 33431
Business Address 777 YAMATO ROAD SUITE 502 BOCA RATON FL 33431 561-589-7020
First Wave BioPharma, Inc. (Filer) CIK: 0001604191 (see all company filings)

IRS No.: 464993860 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37853 | Film No.: 23913377
SIC: 2834 Pharmaceutical Preparations